135 results about "Tumor tissue" patented technology

This invention relates to the field of nanomedicine delivery systems, specifically to an ultrasound-enhanced synergistic immunotherapy drug delivery system, its preparation method, and its applications. The ultrasound-enhanced synergistic immunotherapy drug delivery system includes a lipid shell and a fluorocarbon gas encapsulated within the lipid shell. The lipid shell is made from cancer cell membranes and a lipid membrane formed from synthetic phospholipids. The lipid shell integrates a protein degradation-targeting chimera for degrading PD-L1. This invention combines targeted drug delivery, PD-L1 targeted degradation, and ultrasound enhancement technology to construct an integrated synergistic immunotherapy drug delivery system. Through multi-mechanism synergistic action, it overcomes the bottlenecks of existing PROTAC delivery systems, achieving a highly efficient anti-tumor immune response. This technical solution solves the technical problems of limited tumor tissue penetration and cellular uptake efficiency of PROTAC degrading agents targeting PD-L1, resulting in unsatisfactory delivery effects and promising prospects for widespread application.

The application discloses a LYTAG-Gem compound for enhancing the anti-tumor effect of gemcitabine and application thereof, relates to the technical field of biological medicine, and particularly relates to a gemcitabine (Gem) targeted delivery system based on a lysosome targeting chimera (LYTAC) and application thereof in enhancing the anti-tumor process. 2+ The system is assembled from heavy chain ferritin, Ni 2+ , NTA-PEG5000-DBCO and a targeting ligand TPP-1-N3 in a specific mass percentage, can efficiently load Gem and form a nano compound with a particle size of about 59-79 nm, the system targets tumor cells through heavy chain ferritin, and realizes site-specific release of Gem in cells by means of an endocytosis-lysosome pathway mediated by the LYTAC structure, in-vivo pharmacodynamic experiments show that the LYTAC-Gem compound can significantly inhibit the tumor growth of a KPC pancreatic cancer mouse model, molecular mechanism research further reveals that the LYTAC-Gem compound can down-regulate the expression of PD-L1 protein in tumor tissues, and it is indicated that the LYTAC-Gem compound has the potential to activate an anti-tumor immune response, and the application provides a novel targeted delivery strategy for overcoming the toxic side effects and tumor drug resistance of gemcitabine.

This invention relates to the field of biotechnology, specifically disclosing an aging biomarker capable of marking cellular senescence and its applications. The purpose of this invention is to provide a novel biomarker for assessing cellular senescence and its applications, aiming to address the problem of the lack of highly specific biomarkers for the senescence status of immune cells in tumor tissues in existing technologies, particularly the technical bottleneck of accurately assessing the degree of immune cell senescence in the complex tumor microenvironment.

The present application relates to the field of biomedical technology, and discloses an immune infiltration desert tumor benefit ICI treatment method based on a weighting strategy. The method obtains spatial transcriptome data of tumor tissue of a patient, divides the tumor microenvironment into functional regions through an adaptive grid division algorithm, and extracts a multi-scale feature vector; calculates dynamic weight coefficients of each functional region using a graph attention network, and generates a comprehensive response index after weighted integration; and finally outputs an individualized ICI treatment decision according to the comparison result of the index and a preset threshold. The present application realizes dynamic evaluation of tumor microenvironment heterogeneity based on spatial transcriptome data, and provides ICI treatment response prediction and clinical decision support for patients with immune infiltration desert tumors.

The application discloses a cancer survival prediction method and device based on whole-slice pathological images, and relates to the technical field of medical artificial intelligence and digital pathological image analysis. The method comprises the following steps: acquiring whole-slice pathological images and patient survival information, and performing pretreatment; performing cell detection on the whole-slice pathological images to obtain cell structure data; dividing the whole-slice pathological images into a plurality of image regions, and determining regions of interest; screening the cell structure data in each region of interest to construct a cell subset; sorting the cell structure data according to the distribution relationship of cells in space to construct a cell structure sequence; constructing a cell structure modeling model, performing feature modeling on the cell structure sequence, and obtaining tissue structure features capable of representing the microstructure of tumor tissues; and inputting the tissue structure features into a survival prediction model to predict the survival risk of the patient. The application can improve the accuracy and stability of cancer survival prediction.

This invention relates to an ultrasound endoscope probe, an ultrasound endoscope system, and its working method. The ultrasound endoscope probe includes multiple convex array transducers arranged in an array on a mounting plate. The mounting plate has a retracted position and an extended position. When the mounting plate is in the retracted position, the connecting surface is abutted against the mating inclined surface. When the mounting plate is in the extended position, the working surface is perpendicular to the central axis of the endoscope catheter. The ultrasound endoscope system includes a signal synchronization module, a data acquisition module, a data processing module, and a display module. By constructing a mapping relationship between the probe coordinate system and the BEV global coordinate system, a three-dimensional voxel mesh is generated to segment blood vessels and tumor tissue, ultimately achieving three-dimensional reconstruction. This invention overcomes the shortcomings of traditional ultrasound imaging, such as low vascular discrimination and large three-dimensional reconstruction errors, effectively improving imaging and segmentation accuracy, clearly displaying the relationship between lesions and adjacent blood vessels, shortening operation time, improving the safety of minimally invasive operations, reducing the burden of diagnosis and treatment for patients, and demonstrating significant clinical application value.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The application relates to the technical field of biological medicine, and discloses a micropeptide miPEP060 coded by a LINC00060 gene and application thereof; the application provides the following application of LINC00060 and the micropeptide miPEP060 coded thereby: preparing a product for predicting tumor chemotherapy efficacy, preparing a product for predicting tumor prognosis; preparing a tumor treatment product, preparing a product for enhancing tumor chemotherapy efficacy, preparing a product for overcoming tumor chemotherapy drug resistance, preparing a product for inhibiting PARP1 enzyme activity or PARylation modification, and preparing a product for inhibiting replication stress response and replication fork stability; the LINC00060 and the micropeptide miPEP060 coded thereby provided by the application can significantly enhance the chemotherapy killing effect of tumor cells or tumor tissues and reduce tumor volume.

The application belongs to the technical field of biological medicine, and provides a CXCR4 high expression type iPSC-NK cell with enhanced bone marrow and tumor tissue homing ability, and a preparation method and application thereof. The cell takes pluripotent stem cells as starting cells, overexpresses a membrane-bound IL-15 and IL-15RA fusion protein gene and a CXCR4 receptor gene in the pluripotent stem cells; pluripotent stem cells stably expressing the target gene are obtained, and then iPSC-NK cells are obtained through induction differentiation. The membrane-bound IL-15 and IL-15RA fusion protein gene and the CXCR4 receptor gene are targetedly integrated into a safe harbor site of the induced pluripotent stem cell through a gene editing technology, so as to construct an iPSC cell strain stably expressing key proteins; the function-enhanced iNK cell is obtained through induction differentiation, and exhibits excellent bone marrow and various solid tumor tissue homing ability and persistent immune killing activity.

This invention discloses a bipolar water-cooled ablation electrode structure, relating to the field of ablation needle technology. It includes a handle and a connector slidably connected to the end of the handle, a needle body fixedly connected to the end of the connector, a heat insulation sleeve slidably connected to the outer periphery of the needle body, and a flexible sleeve fixedly connected to the bottom of the heat insulation sleeve. The inner wall of the flexible sleeve is fitted to the outer wall of the bottom end of the needle body. This invention, by providing a slidable heat insulation sleeve on the outer periphery of the needle body, moves the heat insulation sleeve to the edge of the tumor tissue before ablation. Utilizing the physical isolation of the heat insulation sleeve and the cooling of the coolant, it effectively prevents the heat generated during ablation from being conducted to normal tissue. Through the cooperation of the support tube, support rod, and positioning rod in the package, the bottom of the flexible sleeve automatically expands to form an flared shape when the heat insulation sleeve moves, completely covering tumor tissues of different shapes and sizes, ensuring that the ablation area completely covers the tumor while avoiding accidental damage to surrounding normal tissues.

The application discloses a kind of multistage decomposition tumor taking devices, including fixed frame, shell, rotating core, plunger and rotating barrel;The fixed frame is cylindrical structure, and a plurality of positioning needles are provided on the fixed frame;The shell is arranged at the tail of fixed frame, and a positioning assembly is arranged on the shell and used in cooperation with the fixed frame;The rotating core is movably arranged in the shell, and a cutting blade is arranged at the front end of the rotating core;The plunger is arranged between the rotating core and the rotating barrel, and moves along the length direction of the rotating barrel;The rotating barrel is rotatably arranged in the rotating core, and is used in cooperation with the rotating core;Through the setting of fixed frame, shell, rotating core, plunger and rotating barrel, the tumor tissue can be accurately taken out for examination during use, with the characteristics of simple structure, easy to use, high sampling precision and efficiency.

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

This invention is related to the fields of medical biotechnology, nanobiotechnology, and nanomedicine. It involves a nanomedicine product that can release HOC1 (hypochlorous acid) at the tumor site in a controlled manner to treat lung cancer. HOC1 is a potent antimicrobial and antitumor agent that can target tumor tissues while minimizing damage to healthy tissues. The produced nanoparticles have a two-layer structure: the inner layer contains alginate, PFP (perfluoropentane), and Ca(OCl)2 to release HOC1, and the outer layer has a chitosan coating with folate and salicylic acid for targeting and proton release. The production process involves nanoemulsion and coating with the ionic gelation technique. When the nanoparticles are delivered to the lungs and targeted to cancer cells with folate, ultrasound radiation triggers the release of HOC1 to induce apoptosis and destroy cancer cells effectively, reducing side effects and improving treatment outcomes for lung cancer patients.

This invention relates to an integrated gas-liquid separation pulsed negative pressure system for biopsy and transport, comprising a front-end puncture assembly, a mid-end collection and filtration assembly, and a rear-end pulsed negative pressure power assembly. The front-end puncture assembly includes a hollow puncture needle and a hollow handle, with a standard negative pressure interface at the tail of the handle. The mid-end collection and filtration assembly is primarily a collection bottle, with a liquid and air inlet and a negative pressure suction port at the top. Inside the collection bottle is a central interception filter for intercepting solid tumor tissue, below which is a waste liquid sedimentation zone for blood / exudate. The rear-end pulsed negative pressure power assembly is primarily a high-frequency pulsed pneumatic motor connected to the negative pressure suction port. This invention achieves precise two-handed manipulation, stable triggering, pulsed negative pressure separation sampling, efficient specimen collection, and direct transport for testing.

The application relates to the technical field of biopharmaceuticals, and discloses a PD-1 and CTLA-4 double-target inhibiting polypeptide or a pharmaceutically acceptable salt thereof and an application thereof, wherein the polypeptide has a structure as shown in formula (I): X1SPILYQMCDYKRX2 (I). The polypeptide or the pharmaceutically acceptable salt thereof can simultaneously produce high-affinity binding to PD-1 and CTLA-4, has excellent biological blocking activity, can significantly improve the proportion of effector T cell subgroups in tumor tissues, and effectively enhances the anti-tumor immune response of the body. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for related detection of PD-1 and CTLA-4, and can be used as a new anti-tumor candidate drug, thereby providing a brand-new treatment scheme for cancer patients.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

Examples relate to a method comprising using a non-target tissue model to virtually purify an experimental electrical impedance signal with respect to target tissue. A method comprisingobtain a purifying impedance transfer function based on an electrical impedance model with one or more non-target tissue components and without a target tissue component; andpurifying an experimental electrical impedance signal using the purifying impedance transfer function to obtain a virtually purified signal for the target tissue component. A method comprising: in dependence upon age and / or a measure of obesity, access an impedance transfer function dependent upon non-tumor tissue; modify an experimental electrical impedance signal using the obtained impedance transfer function to obtain a signal less dependent upon non-tumor tissue and more dependent upon tumor tissue impedance.

This invention discloses a method for inducing B-CD4 + Freeze-dried tumor tissue with T-cell interaction, its preparation method, and its applications. This study aims to address the lack of effective treatments for postoperative recurrence of microsatellite stable (MSS) solid tumors, the easy degradation and inactivation of traditional autologous whole antigen vaccines, insufficient presentation efficiency, and the limitation of only activating classical CD8. + The core bottleneck of the T cell pathway. This invention utilizes vacuum freeze-drying technology to prepare porous, degradable freeze-dried tumor tissue (LT) from clinically derived or artificially cultured tumor tissue. This process fully preserves the tumor's complete antigen spectrum, tumor-specific antigens, and the immunogenicity of related antigens. It allows for highly efficient antigen presentation via dendritic cells, specifically inducing B cells and CD4+. + T-cell interaction mediates non-classical anti-tumor immunity that does not rely on traditional cytotoxic immune cells, significantly inhibiting the growth of residual lesions after solid tumor surgery. It has both broad-spectrum anti-cancer effects and excellent biosafety, and is especially suitable for postoperative adjuvant immunotherapy for MSS-type colorectal cancer.

The application discloses a low-temperature freezing rotary cutting device and a rotary cutting system for breast tumor diagnosis. The outer tube outer layer and the outer tube inner layer are arranged on the fixing member, and a sampling groove is formed by the slot opening and the sealing structure. The inner tube and the inner cutting blade are arranged in the outer tube inner layer. The sealed cavity formed between the outer tube outer layer and the outer tube inner layer is divided into an expansion cavity and a backflow cavity. The air inlet structure is arranged to extend into the expansion cavity to output the refrigerant. The outer tube outer layer is provided with an insulating material layer to isolate the cold energy transmission. The tumor tissue is sucked into the sampling groove under negative pressure. The refrigerant is released into the expansion cavity through the air inlet structure to expand and cool. The cold energy is transmitted to the sampling groove through the outer tube inner layer to freeze the tumor tissue, so that the original biological elasticity is lost. Then, the tissue is rotary cut by the inner cutting blade on the inner tube, and the cutting efficiency and the sampling efficiency are improved.

The application discloses a nanobody targeting Claudin 18.2 and an application thereof, and belongs to the technical field of molecular biology. In view of the unique advantages of the nanobody in the prior art, the application provides a nanobody targeting Claudin 18.2, wherein the amino acid sequence of the nanobody is shown as SEQ ID NO. 1; the nanobody has strong affinity to 293T-Claudin 18.2 positive cells and can be combined with the Claudin 18.2 protein expressed on the cell surface. The nanobody targeting Claudin 18.2 provided by the application can be prepared by large-scale expression of an in-vitro engineering bacterium, can be applied to preparation of a protein detection antibody or a therapeutic antibody, can be used for in-vitro and in-vivo detection of tumor tissues expressing Claudin 18.2, and has important commercial value in clinical disease diagnosis and treatment.

This invention discloses a method and system for identifying brain tumors in brain MRI images. The method includes the following steps: S1, acquiring the original brain MRI image data of the object to be identified and performing preprocessing operations to obtain standardized multimodal MRI image data; S2, performing preliminary tumor region screening on the preprocessed image data using a tumor tissue probability decoupling identification method based on multi-echo relaxation differences. This invention relates to the field of medical image processing technology. This method and system for identifying brain tumors in brain MRI images employs a tumor tissue probability decoupling model based on multi-echo relaxation differences and cross-scale brain network topology perturbation analysis, which can accurately screen potential tumor regions. Furthermore, it improves identification accuracy through dual constraints of metabolism and morphology. The introduction of cross-scale topology analysis, combined with abnormal propagation detection of brain network structures, effectively identifies suspected tumor regions and improves identification accuracy.

The application discloses a kind of attenuated salmonella load adjuvant nano combination medicine, the combination medicine is modified to bacterial surface by means of amino and carboxyl condensation reaction, adamantane is simultaneously modified to adjuvant nano medicine surface using diselenium dynamic bond, then the host-guest interaction of adamantane and cyclodextrin is used to assemble two, and then nano medicine is stably combined on the surface of attenuated salmonella.Diselenium dynamic bond can be broken by ultrasound response, so as to realize the effect of drug release.This combination medicine has the tumor targeting enrichment ability of bacteria and the release characteristics of adjuvant nanoparticles under the action of ultrasonic wave, can realize targeted delivery and deep penetration in tumor tissue, and obtain significant tumor inhibition effect under ultrasonic stimulation.The experimental results show that the combination medicine exhibits good therapeutic effect in inhibiting tumor growth, and has excellent biological safety.

This invention provides a continuous implantation device for PDX model tumor tissue, comprising: a main cannula; and a pushing component disposed at one end of the main cannula. The continuous implantation device for PDX model tumor tissue provided by this invention utilizes the cooperation of structures such as the main cannula, the pushing component, the tissue sampler, and the retaining spring. The tissue sampler can be pre-loaded with multiple tumor tissue blocks, the retaining spring enables precise positioning and switching of the tissue sampler, the pushing component can sequentially push the tissue blocks for implantation, and the main cannula can be externally connected to an syringe to achieve simultaneous delivery of gel and tissue blocks. This device enables continuous implantation of tumor tissue blocks without the need for repeated clamping and transfer operations, significantly improving implantation efficiency and avoiding the decrease in activity caused by prolonged exposure of tissue blocks outside the body. Furthermore, it eliminates the need for clamping tissue blocks during transfer, reducing the risk of mechanical damage and ensuring the integrity of the tissue blocks. It also enables simultaneous delivery of tissue blocks, gel, and drugs, improving the experimental adaptability of the device.

The subject of the present invention is a novel fluorescent compound that can be used to label tumor tissue, a method for preparing it, and its use as a monitoring or diagnostic or auxiliary tool in relation to cancer surgery.

The application discloses a ROS / GSH responsive hyperbranched zwitterionic micelle and a preparation method and application thereof, and relates to a drug delivery system, ROS responsive zwitterionic micelles and GSH responsive zwitterionic micelles are prepared respectively, the ROS responsive zwitterionic micelles are loaded with anti-angiogenic drugs, and the GSH responsive zwitterionic micelles are loaded with anti-tumor stem cell drugs, so that the combined treatment of blood vessel normalization and tumor stem cell killing is realized, while the blood vessel normalization is realized, the restriction of the small intercellular gap of vascular endothelial cells caused by the blood vessel normalization on the enrichment and penetration of subsequent nano drugs in tumor sites is effectively solved, and the change of the interstitial pressure of tumor tissue caused by the blood vessel normalization is fully utilized to promote the deep penetration of small-size GSH responsive zwitterionic micelles into the internal region of the tumor, so that the killing of tumor stem cells is completed, and the combined treatment of the blood vessel normalization therapy and the tumor stem cell therapy is effectively realized.

This invention provides a method for mining tumor antigens derived from endogenous retroviruses. The method involves bulk RNA-seq sequencing of tumor tissue and adjacent normal tissue samples using a splicing strategy to obtain DNA sequences of human endogenous retrovirus (HERV)-derived transcripts (hervRNA). Subsequently, a specific screening strategy is employed to obtain candidate open reading frames (ORF) sequences on tumor-specific hervRNAs. Finally, homology analysis, prediction of binding energy to human leukocyte antigen class I (HLA-I) molecules, and multi-site analysis are used to predict and mine neoantigens derived from HERV in tumors.

The application provides an image determination method and device and electronic equipment, which can be applied to the technical field of medical image processing. The method comprises the following steps: performing masking on the overlapping area of an anatomical image and a target body surface fluorescent distribution image to obtain a target mask image, wherein the target body surface fluorescent distribution image represents the fluorescent intensity distribution of fluorescent molecules overflowing the body surface of a target object in three-dimensional space; reconstructing the target body surface fluorescent distribution image by using a target reconstruction function to obtain an initial fluorescent molecule tomographic image, wherein the initial fluorescent molecule tomographic image represents the initial density spatial distribution of the fluorescent molecules in tumor tissue; extracting structure prior features corresponding to the target mask image, density spatial features corresponding to the initial fluorescent molecule tomographic image, and optical features corresponding to the target body surface fluorescent distribution image; and fusing the structure prior features, the density spatial features and the optical features based on an attention mechanism to obtain a target fluorescent molecule tomographic image.

FIELD: urology; oncology.SUBSTANCE: used to diagnose the form of bladder cancer in patients with urothelial carcinoma. Tumor tissue is collected. The expression levels of microRNA miR-26b, miR-146b, miR-183 are determined. The obtained values are substituted into the formula for calculating the probability of muscle-invasive bladder cancer (U). If the Y value is above 0.5, muscle-invasive bladder cancer is diagnosed. If the Y value is equal to or lower than 0.5, non-muscle-invasive cancer is diagnosed.EFFECT: method improves the diagnostic accuracy by assessing the expression level of miR-26b, miR-146b, and miR-183.1 cl, 2 ex